<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372695</url>
  </required_header>
  <id_info>
    <org_study_id>MICROBUB-2011-01</org_study_id>
    <secondary_id>2011-002554-30</secondary_id>
    <nct_id>NCT02372695</nct_id>
  </id_info>
  <brief_title>Effect of Paricalcitol Over Vessel Wall</brief_title>
  <acronym>MICROBUB</acronym>
  <official_title>Effect of Paricalcitol Over Vessel Wall: Pleiotropic Analogues Vitamin D Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effice Servicios Para la Investigacion S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació Renal Jaume Arnó</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Effice Servicios Para la Investigacion S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide evidence based prospectives of the potential benefit effects of paricalcitol, an
      analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis
      (vessels), atherosclerosis and vascular calcification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Providing prospective results based on evidence of potential beneficial effects of
      paricalcitol, an analogue of vitamin D in the prevention / delay of progression of
      neoangiogenesis (vessels), atherosclerosis and vascular calcification.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol showed to be inappropriate for the evaluation of the selected patients
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention on vessels progression based on paricalcitol intake.</measure>
    <time_frame>participants will be followed for the duration of whole study, an expected average of 1 year</time_frame>
    <description>Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will take one pill of paricalcitol a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual treatment.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient allocated to this arm will only take his/her habitual treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Zemplar- 1 ug/day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 50 and 75 years.

          -  Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate
             (MDRD).

          -  Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.

          -  Plasma concentrations of 25 (OH) vitamin D &lt;30 ng/ml.

          -  Without vitamin D supplementation for 3 months before the study.

          -  Serum P&gt; 3.8 mg / dl.

          -  Serum Ca&gt; 9.8 mg / dl.

          -  No history of cardiovascular events (angina or myocardial infarction, stroke,
             peripheral arterial disease).

          -  No exclusion criteria for the use of contrast.

        Exclusion Criteria:

          -  Allergic reaction to sulfur hexafluoride.

          -  Recent unstable cardiac symptoms.

          -  Patients with recent coronary intervention (&lt;7 days)

          -  Patients with class III and IV heart failure or severe arrhythmias.

          -  Severe pulmonary hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Vittoria Arcidiacono, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Arnau de Vilanova de Lleida.</affiliation>
  </overall_official>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

